Prices have fallen in the US generics market in the past year due to consolidation among drug retailers, squeezing margins for manufacturers. But Hengrui believes exports can also boost domestic sales.
过去一年,由于药品零售商之间的整合,美国仿制药市场的价格下降,对制药企业的利润形成挤压。但恒瑞医药相信,出口也能提振国内销售。
“You can generate revenue outside of this country but also you give the Chinese patients assurance quality-wise and that’s good for sales in China,” said Mr Zhang. The company is focusing on exports of injectable and inhalable products, which have higher manufacturing standards than tablets and so command higher margins.
张连山说:“你可以在国外创造收入,同时向中国患者做出质量保证,这对中国市场的销售是有利的。”恒瑞医药专注于注射用和吸入用药品的出口,这两类产品的生产标准比片剂更高,因此利润率也更高。
Apart from Hengrui, Chinese companies exporting generics include Zhejiang Huahai Pharmaceutical, which gained eight FDA generic approvals last year, and CSPC Hebei Zhongnuo Pharmaceutical, based near Beijing, which gained five. Shanghai-based Fosun Pharma paid $1.1bn for a majority stake in India’s Gland Pharma last year, which will boost its US generics presence.
除了恒瑞以外,出口仿制药的中国药企还包括浙江华海药业(Huahai Pharmaceutical)和石药集团中诺药业(石家庄)公司(CSPC Hebei Zhongnuo Pharmaceutical),去年这两家公司分别有8款和5款仿制药获得FDA批准。去年,总部位于上海的复星医药(Fosun Pharma)斥资11亿美元收购印度Gland Pharma的多数股份,这将扩大复星医药在美国仿制药市场的地盘。
【中国药企热衷对美出口仿制药】相关文章:
★ 中国哲学的起源
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15